Company news

Emyria Ltd news in 2023

Emyria Ltd's news releases, calls and decks from 2023, newest first.

View company

Board Changes and Executive Restructuring

November 12, 2023

Emyria Secures Ethics Endorsement for MDMA AP Application

October 29, 2023

Emyria hails strong growth in clinical billings

October 26, 2023

September 2023 Quarterly Activities Report and Appendix 4C

October 25, 2023

Health Canada Approval Received for MDMA Import

October 18, 2023

Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone

October 8, 2023

Completion of Entitlement Offer

October 5, 2023

Emyria set to begin MDMA study after securing local supply

September 26, 2023

Emyria Secures Local MDMA to Start PTSD Trial Dosing

September 20, 2023

Emyria Completes Acquisition of the Pax Centre

September 13, 2023

Emyria provides unique combination of drug development and therapy delivery

September 7, 2023

Strategic Update & Entitlement Offer Presentation

September 5, 2023

Prospectus

September 5, 2023

Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer

September 4, 2023

Appendix 4E Preliminary Financial Report

August 30, 2023

Emyria Launches Ketamine-Assisted Therapy Program

August 7, 2023

Emyria advances development and commercialisation of unique drug products

August 1, 2023

June 2023 Quarterly Activities Report and Appendix 4C

July 31, 2023

Emyria Recruits First Patient MDMA-Assisted Therapy Trial

July 9, 2023

Presentation - Pax Acquisition and Company Update

July 5, 2023

Pax Centre Acquisition to Advance Psychedelic Therapies

July 3, 2023

Emyria hails ethics approval for MDMA-assisted clinical trial

June 8, 2023

Emyria Receives Ethics Approval for MDMA-assisted Therapy

June 7, 2023

Emyria Completes $2.5m Placement

May 1, 2023

March 2023 Quarterly Activities Report and Appendix 4C

April 28, 2023

Emyria launches new high potency Ultra-Pure CBD capsule

April 24, 2023

Emyria Unveils Highest Potency CBD Capsule for FDA Pathway

April 23, 2023

Emyria to Develop Psilocybin Therapy Care Model

April 17, 2023

Emyria agrees licensing and commercialisation deal for EMD-RX5

April 4, 2023

Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5

April 3, 2023

Strong Recruitment for EMD-RX5 Phase 3 Trial

March 22, 2023

Emyria Grows MDMA Asset for Neuro & Mental Health Therapy

March 19, 2023

Emyria partners with PAX Centre for MDMA-assisted therapy

March 6, 2023

Half Yearly Report and Accounts

February 26, 2023

Emyria secures clinical-grade MDMA supply for Aust patients

February 12, 2023

Emyria ramps up MDMA programs following ‘incredible’ TGA decision

February 7, 2023

Emyria expands MDMA programs following landmark TGA decision

February 5, 2023

Emyria welcomes dosing of first patient in Phase 3 anxiety trial

January 31, 2023

Appendix 4C - Quarterly

January 30, 2023

First dosing commenced for pivotal EMD-RX5 Phase 3 trial

January 29, 2023

Emyria receives $2.1M R&D tax incentive refund

January 11, 2023

Decks in 2023